

MICROCOPY RESOLUTION TEST CHART URFAU or STANDARDS-1963-A

ADA193263

		REPORT (	OCUMENTATIO	N PAGE			Form Approved OMB No. 0704-0188
1a. REPORT S	ECURITY CLASS	SIFICATION	·····	16. RESTRICTIVE	MARKINGS		
	CLASSIFICATIO			Approved f			; distribution is
ZD. DECLASSI	PICATION / DOV	VNGRADING SCHEDU	LE	unlim	nited.		
		port No. 259	R(\$)	5. MONITORING	ORGANIZATION	REPORT N	UMBER(\$)
		·	Tel- order cynthol	Zo NAME OF N	ONITORING ORG	A \$ (1 7 A T 1 O 2	· · · · · · · · · · · · · · · · · · ·
Genetic '	Toxicology of Toxico		66 OFFICE SYMBOL (If applicable) SGRD-UL-TO-G		omedical Re		and Development
6c. ADDRESS Letterma	(City, State, an n Army Ins		earch	76. ADDRESS(C Ft. Det	ity, State, and Zl		
		Army Medical Lopment Comma	8b. OFFICE SYMBOL (If applicable)  Id SGRD-2A	9. PROCUREMEN	IT INSTRUMENT	DENTIFICA	TION NUMBER
8c. ADDRESS	(City, State, and	d ZIP Code)	<u> </u>	10. SOURCE OF	FUNDING NUMB	ERS	
Fort Det				PROGRAM ELEMENT NO	PROJECT NO.	TASK NO.	WORK UNIT ACCESSION NO
Frederic	k, MD 2170	01-5012		62720A	835	AB	DA 303913
13a. TYPE OF	ne E. Seba REPORT	13b. TIME CO	W. Korte, Jr.	14 DATE OF REPO March		h, Day) 1	Test 5 PAGE COUNT 17
16. SUPPLEM	ENTARY NOTA	IION					
17.	COSATI		18 SUBJECT TERMS (				·
FIELD	GROUP	SUB-GROUP	mutagenicity	, genetic t NITROSO	oxicology, GUANIDINE	Ames to	est,
The Manmaliar TA1537, a The test	mutagenic n Microsom and TA1538 compound	potential of e Mutagenicity were exposed was not mutage	NITROSOGUANIDIN y Test. Tester to doses rangin enic under condi	E was asses strains TA9 g from 1.05 tions of th	7, TA98, TA mg/plate t is test.	100, TA	A102. TA1535.
	SIFIED/UNLIMIT	ED SAME AS F	RPT DTIC USERS	UNC 226 TELEPHONE	lassified	da 1   22c   C	DEFICE SYMBOL
		e, COL, MC		(415) 561		I	U)-UL-Z

### ABSTRACT

The mutagenic potential of NITROSOGUANIDINE was assessed by using the Ames <u>Salmonella/Mammalian Microsome Mutagenicity</u> Test. Tester strains TA97, TA98, TA100, TA102, TA1535, TA1537, and TA1538 were exposed to doses ranging from 1.05 mg/plate to 0.0875 mg/plate. The test compound was not mutagenic under conditions of this test.

Key Words: Mutagenicity, Genetic Toxicology, Ames Test

i	
	Fric \
	1 "OPY
	INSPECTED
	4

Acce	ssion For	
NTIS	GRALI	
DTIC	TAB	ñ
Unan	pounced	ñ
Just	fication	
	ribution/	
	lability	
Dist	Avail and Special	/ <b>0</b> Γ
101		
1 <b>77</b>	1 1	

### PREFACE

TYPE REPORT: Ames Test GLP Study Report

TESTING FACILITY: US Army Medical Research and Development

Command

Letterman Army Institute of Research

Presidio of San Francisco, CA 94129-6800

SPONSOR: US Army Medical Research and Development Command

US Army Biomedical Research and Development

Laboratory

Fort Detrick, Frederick, MD 21701-5010 Project Officer: Gunda Reddy, PhD.

PROJECT/WORK UNIT/APC: 3E162720A835/180/TLBO

GLP STUDY NUMBER: 86008

STUDY DIRECTOR: MAJ Don W. Korte Jr, PhD, MSC

PRINCIPAL INVESTIGATOR: Suzanne E. Sebastian, BA, SP4, USA

REPORT AND DATA MANAGEMENT: A copy of the final report,

study protocol, retired stability

and purity data on the test

compound, and an aliquot of the test

compound will be retained in the

LAIR Archives.

TEST SUBSTANCE: NITROSOGUANIDINE

INCLUSIVE STUDY DATES: 28-30 October, 1986

OBJECTIVE: The objective of this study was to determine the mutagenic potential of NITROSOGUANIDINE (LAIR Code TP 48) by using the Ames <u>Salmonella/Mammalian Microsome Mutagenicity</u>

Test.

### **ACKNOWLEDGMENTS**

MAJ John W. Harbell, PhD, MSC; SGT Lillie D. Witcher, BS; and SGT Gayle A. Orner, BS, provided research assistance.

SIGNATURES OF PRINCIPAL SCIENTISTS AND MANAGERS INVOLVED IN THE STUDY

We, the undersigned, declare that GLP Study 86008 was performed under our supervision, according to the procedures described herein, and that this report is an accurate record of the results obtained.

Afon W. faite 16 FEB 8.

DON W. KORTE, Jr/,/PhD / Date

MAJ, MSC

Study Director

SUZANNE E. SEBASTIAN. BA / DATE

SP4, USA

Principal Investigator

**በርምር ለበመመስመር ለመመስመው በመመስመር እና እና እስር እንደ እስር እንደ እስር እር እንደ እስር እንደ እስር እንደ እስር እንደ እስር እንደ እስር እንደ እስር እንደ እስር** 



### DEPARTMENT OF THE ARMY

### LETTERMAN ARMY INSTITUTE OF RESEARCH PRESIDIO OF SAN FRANCISCO, CALIFORNIA 94129-6800

ATTENTION OF

SGRD-ULZ-QA (70-ln)

23 February 1988

MEMORANDUM FOR RECORD

SUBJECT: Report of GLP Compliance for 86008, Tox Series 148

- 1. I hereby certify that the protocol was reviewed on 29 October 1986.
- 2. The report and raw data for this study were audited on 1 December 1987.

CAROLYN M. LEWIS

C, Quality Assurance

### TABLE OF CONTENTS

Abstracti
Prefaceii
Acknowledgmentsiii
Signatures of Principal Scientistsiv
Report of the Quality Assurance Unitv
Table of Contentsvi
BODY OF THE REPORT
INTRODUCTION
Objective of the Study 1
MATERIALS AND METHODS
Test Compound 2
Test Solvent 2
Chemical Preparation 2
Test Strains 2
Mammalian Microsome System 3
Test Format 3
Data Interpretation 4
Deviations from the Protocol/SOP 5
Storage of the Raw Data and Final Report 5
RESULTS 5
DISCUSSION9
CONCLUSION9
REFERENCES10

APPENDIX	A	• • • • • • •	• • • • • •	• • • • • • •	• • • • • • •	 11
APPENDIX	в			• • • • • •		 13
OFFICIAL DISTR	RIBUTION	LIST				 17

Mutagenic Potential of NITROSOGUANIDINE - Sebastian and Korte

Nitrosoguanidine is an anticipated environmental degradative product of nitroguanidine (1). Nitroguanidine, a primary component of US Army triple-base propellants, is now produced in a Government-owned contractor-operated ammunition plant. The US Army Biomedical Research and Development Laboratory (USABRDL), as part of its charge to evaluate the environmental and health hazards of propellants generated by US Army munitions manufacturing facilities, conducted a review of the nitroguanidine data base and identified significant gaps in the toxicity data (2). The Division of Toxicology, LAIR, was tasked by USABRDL to develop a genetic and mammalian toxicity profile for nitroguanidine and related intermediates/by-products of its manufacture or environmental degradation products.

The Ames <u>Salmonella</u>/Mammalian Microsome Mutagenicity Test is a short-term screening test that utilizes histidine auxotrophic mutant strains of <u>Salmonella typhimurium</u> to detect compounds that are potentially mutagenic in mammals. A mammalian microsomal enzyme system is incorporated in the test to increase sensitivity by simulating <u>in vivo</u> metabolic activation of the test compound. The Ames test is an inexpensive yet highly predictive and reliable test for detecting mutagenic activity and thus carcinogenic potential (3).

This evaluation of NITROSOGUANIDINE utilizes a revision of the Ames <u>Salmonella</u>/ Mammalian Microsome Mutagenicity Test (4). Two new tester strains, a frame-shift strain (TA97) and a strain carrying an ochre mutation on a multicopy plasmid (TA102), are added to the standard tester set.

**ᢊᠪᠪᢑᢊᢑᢊᢑᢊᢑᠻᢑᡊᢑᡊᢘᢧᢛᢧᢛᢧᢛᢧᢛᢧᢎᠧᢌᠬᠵᡊᢐᡊᢐᡊᢐᡳ᠐ᡑᢗᢑᡳᢗᢢ᠒ᢣᠼᢊᠪᡳᢗᢊᢡᡪᡭᠾᡲᡀᡳᢒᡳᡀᠪᡀᠸᡀ᠗᠘ᡚᡚᡓᢢ᠔ᢢ᠘ᡓ᠘ᡧ᠘ᢢ᠘ᢢ᠘ᢢ᠘** 

Sebastian and Korte--2

### Objective of the Study

The objective of this study was to determine the mutagenic potential of NITROSOGUANIDINE (LAIR Code TP 48) by using the revised Ames <u>Salmonella/Mammalian Microsome</u> Mutagenicity Test.

### MATERIALS AND METHODS

### Test Compound

Chemical name: NITROSOGUANIDINE

Code number: LAIR Code No. TP 48

Physical state: White crystalline solid

Source: Alan Rosencrance

US Army Biomedical Research and Development

Laboratory

Fort Detrick, Frederick, MD 21701-5010

Storage: NITROSOGUANIDINE was received from USABRDL and was stored at room temperature (21°C) until used.

Chemical Properties/Analysis: Nitrosoguanidine was characterized for chemical composition and purity by the Division of Toxicology, LAIR (Presidio of San Francisco, CA). The purity of nitrosoguanidine was 97.5% with about 2.5% nitroguanidine. Results of this analysis are presented in Appendix A.

### Test Solvent

The positive control chemicals were dissolved in grade I dimethyl sulfoxide (lot 113F-0450) obtained from Sigma Chemical Co. (St. Louis, MO). The test chemical was dissolved in the same lot of DMSO. Reagent grade water used in this assay was first passed through a Technic Series 300 Reverse Osmosis Unit (Seattle, WA), then through a Corning MP-1 Mega Pure System glass distillation unit (Corning Glass Works, Corning, NY) (5).

### Chemical Preparation

On the day of testing, the compound was dissolved directly into DMSO at a concentration of 15 mg/ml. Aliquots of this solution were used to prepare the serial dilutions.

### Test Strains

Salmonella strains TA97, TA98, TA100, TA102, TA1535, TA1537, and TA1538 obtained from the laboratory of Dr. Bruce Ames, University of California, Berkeley, were used. These strains were maintained in our laboratory at -80°C. Quality control tests were run concurrently with the test substance to establish the validity of their special features and to determine the spontaneous reversion rate. Descriptions of the strains, their genetic markers, and the methods for strain validation are given in the LAIR SOP, OP-STX-1 (6).

### Mammalian Microsome System

The S-9 (batch #R-315) was purchased from Microbiological Associates Inc. (Bethesda, MD). The optimal titer of this S-9, as determined by Microbiological Associates Inc., was 0.75 mg protein/plate.

### Test Format

CONTROL CONTRO

NITROSOGUANIDINE was evaluated for mutagenic potential according to the revised Ames method (4). A detailed description of the methodology is given in LAIR SOP, OP-STX-1 The preincubation modification was chosen to enhance the sensitivity of the assay by exposing the bacteria to higher concentrations of test compound (and the activation products, when present) than was possible in the standard The bacteria were preincubated in plate incorporation assay. the presence of the compound, both with and without metabolic activation, for 20 minutes on a shaker incubator at 37°C. single preincubation tube was prepared for each top agar triplicate. Each preincubation tube contained 10 ml of a mixture which consisted of 1 ml of bacteria (16 hour culture), 1 ml of test compound (15 mg/ml in DMSO or a serial dilution), 2 ml of S-9 mixture if required, and the remaining volume nutrient broth. The highest dose (1.5 mg/ml) in the preincubation mixture approached the practical limits of solubility for nitrosoguanidine in aqueous media (Appendix The top agar tubes were prepared by adding 0.7 ml of the preincubation mixture to 2 ml of top agar. After mixing, the top agar was then overlaid on minimal glucose agar plates. These plates contained 2% glucose and Vogel Bonner "E" concentrate (7). Plates were incubated upside down in the dark at  $37^{\circ}\text{C}$  for 72 hours (Maron 1985, personal communication). Plates were prepared in triplicate and the individual revertant counts were recorded. The average number of revertants at each dose level was compared to the average number of spontaneous revertants (negative control).

The spontaneous reversion rate (with and without S-9) was monitored by averaging the counts from two determinations run simultaneously with the test compound. The spontaneous reversion rate was determined by inoculating one set of plates before and one set after the test compound plates so that any change in spontaneous reversion rate during the dosing procedure would be detected. This spontaneous reversion rate was also compared with historical values for this laboratory and those cited in Maron and Ames (4). Sterility and strain verification controls were run concurrently. All reagents, test compounds, and media were checked for sterility by plating samples of each on MGA media and incubating them at 37°C with the test plates. Salmonella strains were verified by a standard battery of tests. The integrity of the different Salmonella strains used in the assay was verified by the following standard tests:

-Lack of growth (inhibition) in the presence of crystal violet which indicated that the prerequisite alteration of the lipopolysaccharide layer of the cell wall was present.

-Growth in the presence of ampicillin-impregnated disks which indicated the presence of an ampicillin-resistant R Factor in all strains except TA1535, TA1537, and TA1538.

-Lack of growth (inhibition) following exposure to ultraviolet light which indicated the absence of the DNA excision-repair mechanism (for all strains except TA102).

Six known mutagens were tested as positive controls to confirm the responsiveness of the strains to the mutation process. Each strain must be tested with at least one positive control but may be tested with several. These compounds, benzo[a]pyrene (lot 18C-0378), 2-aminofluorene (lot 021547), 2-aminoanthracene (lot 020797), mitomycin-C (lot 015F-0655), 4-nitroquinoline-n-oxide (lot 89C-0710) and N-methyl-N'-nitro-N-nitrosoguanidine (lot 127C-0342), were obtained from Sigma Chemical Co. (St. Louis, MO). The test compound and mutagens were handled during this study in accordance with the standards published in NIH <u>Guidelines for the Laboratory Use of Chemical Carcinogens</u> (DHHS Publication No. (NIH) 81-2385, May 1981).

### Data Interpretation

According to Brusick (8), a compound is considered

mutagenic if a positive dose response (correlated dose response) over three dose concentrations is achieved with at least the highest dose yielding a revertant colony count greater than or equal to twice the spontaneous colony count for the tester strains TA98 and TA100, or three times the spontaneous colony count for strains TA1535, TA1537, and TA1538 (4,6). A strong correlated dose response in strain TA100 without a doubling of the individual colony count may also be considered positive.

Maron and Ames (4) consider a compound mutagenic in tester strains TA97 and TA102 if a correlated dose response over three concentrations is achieved with the highest dose yielding a revertant colony count greater than or equal to twice the spontaneous colony count.

### Deviations from the Protocol/SOP

The preincubation modification of the Ames Assay was chosen to enhance sensitivity by exposing bacteria to a higher concentration of compound, for a longer period of time. Volumes for the preincubation mixture were different from those specified in the SOP because of the limited solubility of nitrosoguanidine. This deviation has no impact on the validity of the study.

### Storage of the Raw Data and Final Report

A copy of the final report, study protocols, raw data, SOPs, and an aliquot of the test compound will be retained in the LAIR archives.

### RESULTS

Normal results were obtained for all sterility and strain verification tests during the Ames Test performed on 21-24 May, 1986 (Table 1). NITROSOGUANIDINE did not induce any appreciable increase in the revertant colony counts relative to those of the negative control cultures (Table 2).

A tabular presentation of raw data is included in Appendix B.

### Sebastian and Korte--6

### TABLE 1

### STRAIN VERIFICATION AND STERILITY TESTING FOR THE MUTAGENICITY DETERMINATION ON NITROSOGUANIDINE (TP 48)

GLP STUDY NUMBER 86008

### STRAIN VERIFICATION

### OBSERVATIONS\*

STRAIN	HISTIDINE REQUIREMENT	AMPICILLIN RESISTANCE	UV REPAIR	CRYSTAL VIOLET	STERILITY CONTROL
TA97	NG	G	NG	NG	NG
TA98	NG	G	NG	NG	NG
TA100	NG	G	NG	NG	NG
TA102	NG	G	G	NG	NG
TA1535	NG	NG	NG	NG	NG
TA1537	NG	NG	NG	NG	NG
TA1538	NG	NG	NG	NG	NG

### STERILITY CONTROL FOR MUTAGENICITY DETERMINATION

MATERIAL TESTED	OBSERVATION*
MINIMAL GLUCOSE AGAR PLATES	NG
TOP AGAR	NG
DILUENT WATER	NG
NUTRIENT BROTH	NG
TEST COMPOUND (HIGHEST DOSE)	NG
S-9	NG

<sup>\*</sup> G = Growth, NG = No Growth

TABLE 2

# NITROSOGUANIDINE

## REVERTANTS/PLATE

### MEAN ± 1SD

COMPOUND*	DOSE/PLATE	TA97	TA98	TA100	TA102
WITHOUT S-9					
NEG CONTROL	0	88 ±16.1	14 ±3.3	111 ±10.2	3 ±13.
MITO C	S.				1327 ±22.5
MINNG	0			1460 ±149.1	
ONON	2.0 µg	±92.			
TP 48	.05	82 ±16.4	+1	3 ±0.	68 ±9.
TP 48	∞.	¥6.	20 ±6.0	110 ±9.6	164 ±11.3
TP 48	φ.	Ħ.	#3	6 ±7.	72 ±13.
TP 48	4	±4.	<del>1</del> 0.	5 ±12	73 ±15.
TP 48	7	±7.	#3	2 ±4.	34 ±21
TP 48	r-1	±16	±4.	3 ±7.	65 ±20.
WITH S-9	1				
NEG CONTROL	0	110 ±16.6	5 ±10.	±21.	282 ±5.4
2-AA	0		98 ±73.	<b>±</b> 86.	
2-AF	0	±13	3 ±42	706 ±86.5	
ВР	0	+7	25 ±7.	±35.	
TP 48	1.05 mg	120 ±14.0	33 ±3.6	103	36 ±18
TP 48	œ	±7.	5 ±5.	<del>1</del> 5.	58 ±16
TP 48	9	÷6.	0 ±8.	105 ±0.7	40 ±4.
TP 48	4	<del>+</del> 9	9 ±12	100	64 ±16
TP 48	7	±7.	1 ±1.	115 ±6.4	228 ±22.7
TP 48	0.1 mg	105 ±22.3	9 ±1.		34 ±26

\*MITO-C=mitomycin-C, MNNG=N-methyl-N'-nitro-N-nitrosoguanidine, NQNO=4-nitroquinoline-n-oxide, AA=2-aminoanthracene, AF=2-aminofluorene, BP=benzo[a]pyrene.

TABLE 2, (Continued)

NITROSOGUANIDINE

# REVERTANTS/PLATE

## MEAN ± 1SD

COMPOUND*	DOSE/PLATE	TA1535	TA1537	TA1538
MITHOUT S-9				
NEG CONTROL	0.	1 ±3.	10 ±3.2	18 ±6.4
MING	20.0 µg	2224 ±378.2		
TP 48	ö	8 ±3.	+3.	5 ±1.
TP 48	ω.	5 ±3.	±2.	4 ±1.
TP 48	0.6 mg	4 ±3.	16 ±9.5	14 ±4.2
TP 48	4	5 ±2.	¥6.	6 ±3.
TP 48	~	9 ±4.	±2.	3 ±2.
TP 48	-	5 ±2.	<del>+</del> 11.	4 ±1.
WITH S-9	•			
NEG CONTROL	0	11 ±1.7	2 ±4	#
2-AA	0		318 ±55.2	72 ±231.
2-AF	2.0 µg			1168 ±173.9
BP	0.		8 ±5.	±39.0
TP 48	.05	1 ±4.	#5.	#3
TP 48	φ.	6 ±9.	9 ±1.	+
TP 48	9.	8 ±2.	5 ±3.	+1
TP 48	4.	0 ±3.	±3.	4
TP 48	۲.	16 ±4.0	10 ±1.0	<del>+</del> 4
TP 48	۲.	0 ±1.	±3.	#

\*MITO-C=mitomycin-C, MNNG=N-methyl-N'-nitro-N-nitrosoguanidine, NQNO=4-nitroquinoline-n-oxide, AA=2-aminoanthracene, AF=2-aminofluorene, BP=benzo[a]pyrene.

### DISCUSSION

Certain test criteria must be satisfied before an Ames test can be considered a valid assessment of a compound's mutagenic potential. First, the special features of the Ames strains must be verified. These features include demonstration of ampicillin resistance, alterations in the lipopolysaccharide layer, and deficiency in DNA excision-repair (except TA102). Second, the <u>Salmonella</u> strains must be susceptible to mutation by known mutagens. Third, the optimal concentration of the test compound must be determined by treating TA100 with a broad range of doses and observing the potential toxic effects on formation of macrocolonies and microcolonies. If these tests are performed and expected data are obtained, then the results of an Ames test can be considered valid.

After validation of bacterial strains and selection of optimal sublethal doses, NITROSOGUANIDINE was evaluated in the Ames preincubation test. Criteria for a positive response include both a correlated dose response over three dose concentrations, and a revertant colony count at least two times (TA97, TA98, TA100, TA102) (3,8) or three times (TA1535, TA1537, TA1538) (4,6) the spontaneous revertant colony count. NITROSOGUANIDINE did not induce the requisite dose-response relationship or the increase in revertant colony counts necessary for a positive response. Thus, the results of this test indicate that NITROSOGUANIDINE is not mutagenic when evaluated in the Ames test.

### CONCLUSION

NITROSOGUANIDINE, both in the presence and absence of metabolic activation, was evaluated for mutagenic potential in the Ames test, and did not induce a positive mutagenic response under conditions of this study.

### REFERENCES

- 1. Kaplan DL, Cornell JH, Kaplan AM. Decomposition of nitroguanidine. Environ Sci Technol 1982: 16:488-492.
- Kenyon KF. A data base assessment of environmental fate aspects of nitroguanidine. Frederick, Maryland: US Army Bioengineering Research and Development Laboratory, 1982, DTIC No. ADA 125591.
- 3. Ames BN, McCann J, Yamasaki E. Methods for detection of carcinogens and mutagens with <u>Salmonella/Mammalian</u> Microsome Mutagenicity Test. Mutat Res 1975;31:347-364.
- 4. Maron DM, Ames BN. Revised methods for the <u>Salmonella</u> Mutagenicity Test. Mutat Res 1983;113:173-215.
- 5. Operation of the Technic Model 301 Reverse Osmosis Pre-Treatment Water System and the Corning Model MP-1 Glass Still. LAIR Standard Operating Procedure OP-STX-94, Presidio of San Francisco, California: Letterman Army Institute of Research, 29 July 1985.
- 6. Ames <u>Salmonella</u>/Mammalian Microsome Mutagenesis Test. LAIR Standard Operating Procedure OP-STX-1, Presidio of San Francisco, California: Letterman Army Institute of Research, 29 August 1986.
- 7. Vogel HJ, Bonner DM. Acetylornithinase of <u>E. coli</u>: Partial purification and some properties. J Biol Chem 1956:218:97-106.
- 8. Brusick D. Genetic toxicology. In: Hayes AW, ed. Principles and methods of toxicology. New York: Raven Press, 1982:223-272.

### APPENDIX A


### CHEMICAL DATA

Chemical Name: Nitrosoguanidine

Chemical Abstracts Service Registry No.: 674-81-7

Lot Number: WCC-2-002

LAIR Code: TP 48
Chemical Structure:



Molecular Formula: CH4N4O

Molecular Weight: 88

Physical State: yellow powder

Analytical Data:

Nitrosoguanidine was analyzed by HPLC using conditions similar to those employed by Burrows et al.1 Conditions were as follows: column, Brownlee RP-18 (4.6 mm x 25 cm); mobile phase, water; flow-rate, 0.8 ml/min. The effluent was monitored at 255 nm. The retention times for nitrosoguanidine and nitroguanidine were 4.4 and 6 min, respectively. The HPLC data demonstrated that the nitrosoguanidine contained approximately 2.5% nitroguanidine.2 IR (KBr) 3378, 3096, 1690, 1649, 1508, 1341, 1266, 1134, 1088, 1035, 690, 668 cm-1.3

Solubility:

A saturated solution of nitrosoguanidine in water was prepared at room temperature. A 1:500 dilution of this solution produced an absorbance of 0.533 units. Using an extinction coefficient of 13,305 L/moles.cm, the concentration of nitrosoguanidine in the original saturated solution was calculated to be 1.763 mg/ml.4

Stability:

Stable for at least 4 hours in HEPES buffer (pH 7.3) at  $37^{\circ}\text{C.}5$ 

Source: Alan Rosencrance

US Army Medical Bioengineering Research

and Development Laboratory Fort Detrick, Maryland

Sebastian and Korte--12

IBurrows EP, Brueggeman EE, Hoke SH. Chromatographic trace analysis of guanidine, substituted guanidines and s-triazines in water. Chromatog 1984;16:494-8.

2Wheeler CR. Nitrocellulose-Nitroguanidine Projects.

Laboratory Notebook #84-05-010.3, p 37. Letterman Army Institute of Research, Presidio of San Francisco, CA.

3Ibid. p 30.

4Wheeler CR. Nitrocellulose-Nitroguanidine Projects.

Laboratory Notebook #85-01-006, p 66. Letterman Army Institute of Research, Presidio of San Francisco, CA.

5Wheeler CR. Nitrocellulose-Nitroguanidine Projects.

Laboratory Notebook #84-05-010.3, p 46. Letterman Army Institute of Research, Presidio of San Francisco, CA.

<u>ቔ፞፞፞ዾ፝ቔቔ፟ዸጜፚጜፚጜፚቔ፟፟ፚ፟ጜዹ፟ጚዄኯፚጜዄጜፚቜፚፙዄጜቜቔፚጚዾጜጟጜዄኇፚቔፚቔፚቜቔፚቔጜጜጜዄኯፚጚፚቔፚቔፚጜጜጜጟፙጟዄጜፚጜ</u>

APPENDIX B-1

RAW DATA TABLE REVERTANTS/PLATE

NITROSOGUANIDINE (TP 48)

COMPOUND	DOSE/PLATE	TA97	TA98	TA100	i	TA102 TA1535 TA1537 TA1538	TA1537	TA1538
HITHOUT S-9								
NEG CONTROL (START RUN)	O.0 mg	101 79 61	14 12 10	105 107 97	178 193 174	16 8 11	11 14 13	21 24 26
NEG CONTROL (END RUN)	0.0 mg	100 101 85	12 16 19	115 126 117	158 159 178	12 10 8	ထပထ	13 10 15
WITH S-9								
NEG CONTROL (START RUN)	0.0 mg	104 92 100	45 36 46	134 116 99	283 275 280	13 9 13	10 18 6	26 29 72
NEG CONTROL (END RUN)	0.0 mg	140 113 113	36 29 17	ር ል * *	288	12 10 10	15 12 11	28 22 27
*plate contaminat	inated							

APPENDIX B-2 RAW DATA TABLE POSITIVE CONTROLS: REVERTANTS/PLATE

COMPOUND*	COMPOUND* DOSE/PLATE TA97	TA97	TA98	TA100	TA102	TA102 TA1535 TA1537	TA1537	
	2.0 <b>µ</b> g		377 285 232	363 476 649			276 266 313	3 8 0 6 3 4 6 4 6
	2.0 µg	730 501 486	1683 1641 1726	682 634 802				1235 1299 971
	2.0 µg	244 259 251	118 133 125	335 405 357			46 55 44	43 62 118
	0.5 µg				1341 1339 1301			
	2.0 µg			1601 1304 1475				
	20.0 µg					1801 2340 2530		
	2.0 µg	289 147 320						

**የምምስምም ያንድር በንድርናር ያለው በባር የሆር ሆር ሆር ሆር ነገር እንደነ**ለች እንደነለገ እና እርስ አንዚላ እንደነለገ እና እርስ አንዚላ እንደነለገ እና እርስ አንዚላ እንደ

\*MITO-C=mitomycin-C, MNNG=N-methyl-N'-nitro-N-nitrosoguanidine, NQNO=4-nitroquinclinen-oxide, AA=2-aminoanthracene, AF=2-aminofluorene, BP=benzo[a]pyrene.

APPENDIX B-3
RAW DATA TABLE
REVERTANTS/PLATE
NITROSOGUANIDINE (TP 48)

である。 のでは、 のでは、

6-7
֓֞֞֞֞֩֟֩֟֩֟֩֟֩֟֡֟֩֟֩֟֡֟֡֟֩֟֩֟
ġ
3
-

COMPOUND	DOSE/PLATE TA97	TA97	TA98	TA100	TA102	TA1535	TA1537	TA1538
TP 48	1.05 mg	70	25	107	171	21	15	15
		101	17	108	176	20	10	16
		92	20	*	158	14	თ	
TP 48	. 8 . 0	94	9	114	170	19	σ	
•	)	94	14	117	171		, [	
		83	26	66	151	13	13	15
TP 48	0.6 mg	91	17	9/	157		26	15
	ı	06	13	84	182	15	15	17
		93	10	69	178	10	7	6
TP 48	0.4 mg	75	25	115	$\infty$	13	თ	20
	1	92	14	91	183	14	17	13
		83	15	111	5	18	4	15
TP 48	0.2 mg	79	18	105	~		თ	
	1	91	22	104	158	23	13	14
		93	16	97	2		თ	
TP 48	0.1 mg	65	15	101	7	17	9	
	•	76	თ	97	142	12	7	14
		87	17	111	α	15	∞	
*plate contamin	aminated							

APPENDIX B-4
RAW DATA TABLE
REVERTANTS/PLATE
NITROSOGUANIDINE (TP 48)

### ILTH S-9

COMPOUND TP 48	ND DOSE/PLATE 1.05 mg	TA97 135 119 107	1A98 32 37 30	103 103 *	TA102 217 238 254	TA1535 16 8 9	TA1537 7 18 9	TA1538 25 29 31
TP 48	0.8 mg	113 99 112	35 30 <b>4</b> 0	126 121 131	275 256 243	26 11 10	8 8 10	33 19 28
TP 48	0.6 mg	106 118 114	21 37 32	104 105 *	237 245 237	17 16 20	15 18 11	29 20 21
TP 48	0.4 mg	128 147 139	15 34 39	100	266 279 247	11 6 12	12 9 16	21 20 20
TP 48	0.2 mg	108 120 122	23 20 21	119 108 119	245 202 236	20 17 12	9 10 11	22 19 27
TP 48	0.1 mg	114 122 80	30 28 30	134	205 255 243	911 *	6 4 11	11 25 28
*plate	*plate contaminated							

### Distribution List

Commander
US Army Biomedical Research and
Development Laboratory (27)
ATTN: SGRD-UBZ-C
Fort Detrick, Frederick, MD 21701-5010

Defense Technical Information Center (DTIC) (2)
ATTN: DTIC-DLA
Cameron Station
Atexandria, VA 22304-6145

US Army Medical Research and Development Command (2) ATTN: SGRD-RMI-S Fort Detrick, Frederick, MD 21701-5012

Commandant Academy of Health Sciences, US Army ATTN: AHS-CDM Fort Sam Houston, TX 78234

Chief USAEHA Regional Division, West Fitzsimmons AMC Aurora, CO 80045

Chief USAEHA Regional Division, North Fort George G. Meade, MD 20755

Chief USAEHA Regional Division, South Bldg. 180 Fort McPherson, GA 30330

Commander
USA Health Services Command
ATTN: HSPA-P
Fort Sam Houston, TX 78234

Commandant
Academy of Health Sciences
United States Army
ATTN: Chief, Environmental
Quality Branch
Preventive Medicine Division
(HSHA-IPM)
For Sam Houston, TX 78234

Commander US Army Materiel Command ATTN: AMSCG 5001 Eisenhower Avenue Alexandria, VA 22333

Commander
US Army Environmental Hygiene
Agency
ATTN: Librarian, HSDH-AD-L
Aberdeen Proving Ground, MD 21010

Dean
School of Medicine
Uniformed Services University of the
Health Sciences
4301 Jones Bridge Road
Bethesda, MD 20014

Commander US Army Materiel Command ATTN: AMCEN-A 5001 Eisenhower Avenue Alexandria, VA 22333

HQDA ATTN: DASG-PSP-E Falls Church, VA 22041-3258

HQDA ATTN: DAEN-RDM 20 Massachusetts, NW Washington, D.C. 20314 END DATE FILMED DTIC July 88